Exicure Inc. (XCUR)
9.11
0.49 (5.68%)
At close: Jan 15, 2025, 3:59 PM
9.14
0.33%
After-hours Jan 15, 2025, 04:00 PM EST
Company Description
Exicure, Inc., a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology.
Its lead program candidate includes SCN9A that is in preclinical studies for neuropathic and chronic pain.
The company has a collaboration, option, and license agreement with AbbVie Inc. to develop SNA-based treatments for hair loss disorders; and collaboration agreement with Ipsen S.A. to research, develop, and commercialize novel spherical nucleic acids for Huntington's disease and Angelman syndrome.
Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.
Exicure Inc.
| Country | United States |
| IPO Date | May 22, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 5 |
| CEO | Paul Kang |
Contact Details
Address: 2430 North Halsted Street Chicago, Illinois United States | |
| Website | https://www.exicuretx.com |
Stock Details
| Ticker Symbol | XCUR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001698530 |
| CUSIP Number | 30205M101 |
| ISIN Number | US30205M2008 |
| Employer ID | 81-5333008 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Paul Kang | Chief Executive Officer, President & Director |
| Jiyoung Hwang | Chief Financial Officer, Secretary & Director |
| Joshua Miller | Chief Accounting Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 06, 2025 | 8-K | Current Report |
| Dec 26, 2024 | 8-K | Current Report |
| Dec 26, 2024 | 8-K/A | [Amend] Current Report |
| Dec 23, 2024 | 3 | Filing |
| Dec 23, 2024 | SCHEDULE 13G | Filing |
| Dec 20, 2024 | 8-K | Current Report |
| Dec 17, 2024 | 8-K | Current Report |
| Dec 11, 2024 | 8-K | Current Report |
| Dec 02, 2024 | DEF 14A | Filing |
| Nov 29, 2024 | SC 13D | Filing |